Mitragynine pseudoindoxyl is an emerging kratom-related compound that has recently gained attention because of its connection to 7-OH, synthetic kratom derivatives, and federal scheduling actions. While the name sounds highly technical, the concern is simple: mitragynine pseudoindoxyl may act on opioid receptors and may appear in products that are marketed as kratom alternatives, enhanced extracts, or legal replacement products.
For someone using these products, the biggest risk is not always knowing exactly what they are taking. A product may be sold online or in a smoke shop with packaging that looks professional, natural, or supplement-like. But that does not mean the substance inside is mild, safe, or well understood.
Mitragynine pseudoindoxyl is not the same as plain kratom leaf. It is a chemically distinct compound related to mitragynine, the primary alkaloid found in kratom. It has been studied for opioid receptor activity and has now been named alongside 7-OH, MGM-15, and MGM-16 in federal concern around 7-OH-related substances.
At Wildwood, we believe people deserve clear information without shame. If you have been using mitragynine pseudoindoxyl, 7-OH, MGM-15, MGM-16, or other kratom-related products and feel like stopping has become difficult, help is available.
What Is Mitragynine Pseudoindoxyl?
Mitragynine pseudoindoxyl, sometimes abbreviated as MP, is a compound related to mitragynine, one of the main alkaloids associated with kratom. It is not the same as traditional kratom leaf, and it should not be treated as a basic herbal supplement.
Scientific research has described mitragynine pseudoindoxyl as an opioid receptor-active compound. One widely cited study reported that mitragynine pseudoindoxyl acts as a mu-opioid receptor agonist and delta-opioid receptor antagonist, producing opioid-like pain-relieving effects in preclinical models.
In plain language, that means mitragynine pseudoindoxyl interacts with parts of the brain and body involved in opioid effects. This is why public health officials are concerned about products that contain mitragynine pseudoindoxyl or similar compounds.
Is Mitragynine Pseudoindoxyl the Same as Kratom?
No. Mitragynine pseudoindoxyl is not the same as kratom.
Kratom comes from the leaves of the Mitragyna speciosa plant. It contains multiple alkaloids, including mitragynine and small amounts of 7-hydroxymitragynine. Mitragynine pseudoindoxyl is a distinct compound that can be connected to mitragynine chemistry, but it is not the same thing as plain kratom leaf.
This matters because many people see “kratom-related” language and assume the product is natural or low-risk. But when a product contains concentrated, converted, enhanced, or synthetic compounds, the risk profile can change dramatically.
A person may think they are taking a kratom product when they are actually taking something much stronger or less studied.
Why Are Federal Agencies Concerned About Mitragynine Pseudoindoxyl?
In July 2026, the DEA announced that it had sent two Notices of Intent to the Federal Register involving 7-OH and related substances. One notice addressed 7-OH above a specified threshold. The second addressed 7-hydroxymitragynine-related substances, including mitragynine pseudoindoxyl, MGM-15, and MGM-16.
This means mitragynine pseudoindoxyl is being viewed by federal agencies as part of a broader public health concern around powerful kratom-related opioid-like compounds.
The concern is not just the chemistry. It is the way these substances may enter the consumer market. People may buy products that are mislabeled, inconsistently dosed, or marketed in ways that minimize the risks. Some products may be sold as “legal highs,” “kratom alternatives,” “7-OH replacements,” or stronger extracts, even though the safety profile may be poorly understood.
Why Mitragynine Pseudoindoxyl May Be Risky
The risk with mitragynine pseudoindoxyl comes from both what researchers know and what consumers may not know.
Research has shown that mitragynine pseudoindoxyl can interact with opioid receptors. More recent public health discussion has also identified products containing mitragynine pseudoindoxyl as a concern because these products may not be present in traditional kratom leaf and may be sold as novel formulations.
Potential risks may include:
- Opioid-like effects
- Tolerance
- Dependence
- Withdrawal symptoms
- Cravings
- Sedation
- Impaired coordination
- Increased risk when combined with alcohol, benzodiazepines, opioids, or sleep medications
- Unclear dosing
- Misleading labels
- Switching from one analog to another to avoid withdrawal
- Return to illicit opioids if the product becomes unavailable
For people with a history of opioid use disorder, mitragynine pseudoindoxyl may be especially risky. Even if a product is sold legally or marketed as plant-based, the body may respond to opioid-like effects in ways that feel familiar: relief, tolerance, withdrawal, craving, and loss of control.
Can Mitragynine Pseudoindoxyl Cause Withdrawal?
There is limited real-world clinical data on mitragynine pseudoindoxyl withdrawal specifically. However, because it is an opioid receptor-active compound, dependence and withdrawal are reasonable concerns, especially when products are used daily, frequently, or at high doses.
Possible withdrawal symptoms from opioid-like substances may include:
- Sweating
- Chills
- Anxiety
- Restlessness
- Insomnia
- Muscle aches
- Nausea
- Diarrhea
- Runny nose
- Watery eyes
- Fatigue
- Low mood
- Irritability
- Strong cravings
The pattern may look similar to what people report with concentrated 7-OH products or high-potency kratom extracts. Someone may begin using the product for relief, energy, mood, or to avoid opioid withdrawal, then find that they need it just to feel normal.
Mitragynine Pseudoindoxyl vs. 7-OH
Mitragynine pseudoindoxyl and 7-OH are related in the broader kratom-derived and kratom-adjacent drug market, but they are not identical.
7-OH, or 7-hydroxymitragynine, is an alkaloid associated with kratom that has become widely discussed because of concentrated products sold as tablets, shots, gummies, and powders. Mitragynine pseudoindoxyl is a separate compound that has been studied for opioid receptor activity and has also appeared in concern around novel kratom-related products.
| Comparison Point | Mitragynine Pseudoindoxyl | 7-OH |
|---|---|---|
| Full name | Mitragynine pseudoindoxyl | 7-hydroxymitragynine |
| Common abbreviation | MP | 7-OH |
| Relationship to kratom | Related to mitragynine chemistry | Alkaloid associated with kratom |
| Same as plain kratom leaf? | No | No, especially when concentrated |
| Opioid receptor concern | Yes | Yes |
| Federal concern | Named in DEA action involving 7-OH-related substances | Named in DEA action involving 7-OH above a specified threshold |
| Main consumer risk | Novel products, unclear potency, opioid-like dependence risk | Concentrated products, dependence, withdrawal, opioid-like risks |
The key takeaway is that neither mitragynine pseudoindoxyl nor concentrated 7-OH should be treated as harmless simply because sellers may use kratom-related branding.
Mitragynine Pseudoindoxyl, MGM-15, and MGM-16
Mitragynine pseudoindoxyl is often discussed alongside MGM-15 and MGM-16 because all three were named in the DEA’s 2026 action involving 7-OH-related substances.
MGM-15 is also known as dihydro-7-hydroxymitragynine. MGM-16 is a 9-fluoro derivative of 7-hydroxymitragynine. Mitragynine pseudoindoxyl is different from both, but all three raise similar concerns: they are not ordinary kratom leaf, they may be marketed as newer or stronger alternatives, and they may carry opioid-like risks.
This is important because drug markets often shift after enforcement actions. If 7-OH becomes harder to sell, some companies may attempt to promote other compounds as replacements. A person who is dependent on 7-OH may be tempted to switch to mitragynine pseudoindoxyl, MGM-15, MGM-16, or another analog to avoid withdrawal.
That can be dangerous. Replacing one unregulated opioid-like product with another does not solve dependence. It often adds more uncertainty.
Why “Kratom Alternative” Products Can Be Misleading
Many people do not set out to misuse a drug. They buy something that looks legal, accessible, and less dangerous than illicit opioids. Some may be trying to manage pain. Others may be trying to avoid returning to fentanyl, heroin, or prescription opioids. Some may be using these products for anxiety, sleep, mood, or energy.
The problem is that marketing can blur the truth.
A product can say “kratom,” “plant-based,” “natural,” or “wellness” while containing concentrated or chemically altered compounds that behave very differently from plain leaf. A product can be sold online and still be unsafe. A product can be legal today and restricted tomorrow. A product can seem helpful at first and still lead to dependence.
The body does not care what the package says. It responds to the substance.
What Should You Do If You Are Using Mitragynine Pseudoindoxyl?
If you are using mitragynine pseudoindoxyl, 7-OH, MGM-15, MGM-16, or another kratom-related product, it may be time to look honestly at your relationship with it.
You may want help if:
- You use the product every day
- You feel sick, anxious, or restless when you stop
- You wake up needing a dose
- You are taking more than you planned
- You are spending more money than intended
- You are hiding use from family, coworkers, or recovery supports
- You have tried to stop and could not
- You are using it to avoid opioid withdrawal
- You are worried about legal changes or losing access
- You are thinking about switching to another substance
You do not have to wait until things get worse. Early support can prevent a difficult situation from becoming a crisis.
Treatment for Mitragynine Pseudoindoxyl and Related Products
There is no one-size-fits-all treatment plan for mitragynine pseudoindoxyl use. The right approach depends on the person’s symptoms, substance use history, medical needs, mental health, and risk of returning to opioids or other substances.
Treatment may include:
- Medical assessment
- Withdrawal support
- Residential treatment
- Partial hospitalization programming
- Intensive outpatient treatment
- Individual therapy
- Group therapy
- Relapse prevention planning
- Family support
- Medication-assisted treatment when clinically appropriate
For people experiencing opioid-like withdrawal or cravings, medication-assisted treatment may be considered by a qualified provider. MAT may include medications such as buprenorphine, methadone, or naltrexone, along with counseling and recovery support.
MAT is not a sign of failure. It can be a practical, evidence-based way to reduce cravings, improve stability, and lower the risk of returning to more dangerous substances.
How Wildwood Can Help
Wildwood helps people who are struggling with substance use, dependence, withdrawal concerns, and co-occurring mental health symptoms. If mitragynine pseudoindoxyl or another kratom-related product has become difficult to stop, you do not have to figure it out alone.
Our team can help you understand your options, stabilize safely, and build a treatment plan that does not depend on unregulated products or replacement compounds.
Mitragynine pseudoindoxyl may sound like a new and complicated substance, but the core issue is familiar: when an opioid-like product starts controlling your day, support matters.
If you are worried about withdrawal, cravings, or what happens next, Wildwood is here to help.
Sources
Drug Enforcement Administration. (2026, July 1). DEA to temporarily schedule 7-OH and related substances to protect public safety. U.S. Department of Justice. https://www.dea.gov/press-releases/2026/07/01/dea-temporarily-schedule-7-oh-and-related-substances-protect-public
U.S. Department of Health and Human Services. (2026, July 1). HHS, FDA commend DEA action against dangerous enhanced 7-OH products. https://www.hhs.gov/press-room/hhs-fda-support-dea-7-oh-scheduling.html
U.S. Food and Drug Administration. (2025, July 29). FDA takes steps to restrict 7-OH opioid products threatening American consumers. https://www.fda.gov/news-events/press-announcements/fda-takes-steps-restrict-7-oh-opioid-products-threatening-american-consumers
Váradi, A., Marrone, G. F., Palmer, T. C., Narayan, A., Szabó, M. R., Le Rouzic, V., Grinnell, S. G., Subrath, J. J., Warner, E., Kalra, S., Hunkele, A., Pagirsky, J., Eans, S. O., Medina, J. M., Xu, J., Pan, Y.-X., Borics, A., Pasternak, G. W., McLaughlin, J. P., & Majumdar, S. (2016). Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. Journal of Medicinal Chemistry, 59(18), 8381–8397. https://pmc.ncbi.nlm.nih.gov/articles/PMC5344672/
Center for Forensic Science Research and Education. (n.d.). Mitragynine pseudoindoxyl. NPS Discovery. https://www.cfsre.org/nps-discovery/monographs/mitragynine-pseudoindoxyl
Hill, K., Skolnick, P., Negus, S. S., & McCurdy, C. R. (2025). De facto opioids: Characterization of novel 7-hydroxymitragynine and mitragynine pseudoindoxyl products. Johns Hopkins University. https://pure.johnshopkins.edu/en/publications/de-facto-opioids-characterization-of-novel-7-hydroxymitragynine-a/